Mafenide Acetate
Pronunciation: MAF-en-ide AS-e-tate
Class: Topical anti-infective
Trade Names
Sulfamylon
- Powder for solution, topical 5%
- Cream, topical 85 mg per gram
Pharmacology
Mechanism of action is unknown; however, it is different from sulfonamides.
Pharmacokinetics
Absorption
Topical mafenide is delivered to burned tissue over a 4-h period following application. Peak concentrations of the cream and solution formulations in burned skin occur at 2 and 4 h, respectively. Following application of the cream, plasma C max occurs in 2 h with levels ranging from 26 to 197 mcg/mL.
Metabolism
Once absorbed, mafenide is rapidly converted to an inactive metabolite.
Elimination
The metabolite is eliminated through the kidneys. Parent drug and the metabolite blood levels decrease to pretreatment levels within 24 h after application.
Indications and Usage
CreamUse as adjunctive treatment of second- and third-degree burns.
SolutionUse as an adjunctive topical antimicrobial agent to control bacterial infections when used under moist dressings over meshed autografts or excised burn wounds.
Contraindications
Standard considerations. It is not known if there is cross-sensitivity to other sulfonamides.
Dosage and Administration
Adults and Children 3 mo of age and olderTopical
CreamApply 1 to 2 times daily, to a thickness of about 1/ 16 inch.
SolutionCover grafted area with 1 layer of fine mesh. Cut an 8-ply burn dressing to the size of the graft and wet with mafenide acetate 5% solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable. If irrigation tubing is not used, the gauze dressing may be moistened every 6 to 8 h as needed to keep it wet. Safety and efficacy have not been established for treatment longer than 5 days for an individual graft procedure.
General Advice
- Cream
- Apply with a sterile gloved hand.
- Keep burned area covered at all times, reapplying to any area from which the cream has been removed.
- Dressings usually are not required. However, if a dressing is necessary, apply only a thin layer of dressing.
- Patient should be bathed daily to aid in debridement.
- Continue treatment until healing is progressing well or until the burn site is ready for grafting.
- Solution
- If wetted with irrigation tubing, place the tubing over the burn dressing in contact with the wound and cover with a second piece of 8-ply dressing.
- Secure irrigation dressing with a bolster dressing.
- Keep gauze wet.
- Wound dressings may be left undisturbed, except for the irrigations, for up to 5 days. Additional soaks may be initiated until graft take is complete.
- Maceration of the skin may result from wet dressings applied for intervals as short as 24 h.
Storage/Stability
SolutionStore undiluted packets at 59° to 86°F. Store prepared solution at 59° to 86°F for up to 28 days in an unopened container. Once container is opened, any unused solution must be discarded within 48 h.
CreamAvoid temperatures above 104°F. Protect from light.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
Dermatologic
Rash (5%); itching (3%); blisters; erythema; facial edema; hives; swelling.
Hematologic-Lymphatic
Bone marrow depression (rare); eosinophilia; fatal hemolytic anemia.
Local
Burning sensation; pain.
Metabolic-Nutritional
Decreased pCO 2 ; increased serum chloride; metabolic acidosis.
Respiratory
Hyperventilation; tachypnea.
Miscellaneous
Acute porphyria (rare).
Precautions
MonitorMonitor the site for bacterial growth during interruption of treatment (eg, acidosis, allergic reaction). Monitor acid-base balance, especially in patients with extensive second-degree or partial-thickness burns, and in those patients with pulmonary or renal dysfunction. |
Pregnancy
Category C .
Lactation
Undetermined.
Children
Safety and efficacy not established in children younger than 3 mo of age.
Elderly
Safety and efficacy not established.
Hypersensitivity
If allergic reactions occur, consider discontinuing treatment.
Renal Function
Use with caution in patients with acute renal impairment.
Sulfite Sensitivity
Mafenide cream contains sodium metabisulfite, which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or severe asthmatic episodes in susceptible people.
Acidosis
May occur. If acidosis becomes difficult to control, discontinuing the soaks for 24 to 48 h may aid in restoring acid-base balance.
Fungal colonization
May occur concurrently with reduction of bacterial growth in the burn wound. Systemic fungal infection through the burn wound is rare.
Hemolytic anemia
Fatal hemolytic anemia with DIC, presumably related to G-6-PD deficiency, has been reported.
Hyperventilation
Masked hyperventilation with resulting respiratory alkalosis has occurred.
Metabolic acidosis
May occur as a result of carbonic anhydrase inhibition, usually compensated by hyperventilation. The carbonic anhydrase inhibition may be exaggerated in patients with renal function impairment.
Overdosage
Symptoms
Data are lacking.
Patient Information
- Advise patients to notify their health care provider if condition worsens, if irritation occurs, or if hyperventilation occurs.
- Advise patients using mafenide cream to bathe burned area daily; a whirlpool bath is particularly helpful.
Copyright © 2009 Wolters Kluwer Health.
More Mafenide Acetate resources
- mafenide topical Concise Consumer Information (Cerner Multum)
- Sulfamylon Prescribing Information (FDA)
- Sulfamylon Monograph (AHFS DI)
- Sulfamylon Topical Advanced Consumer (Micromedex) - Includes Dosage Information
- Sulfamylon cream MedFacts Consumer Leaflet (Wolters Kluwer)


